Results 1 to 10 of about 971 (151)
Aspirin and Clopidogrel Resistance [PDF]
Mayo Clinic Proceedings, 2006 Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays.
Erin D. Michos +4 more
+9 more sources
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +4 more sources
TMAO: a potential mediator of clopidogrel resistance [PDF]
Scientific Reports, 2021 Trimethylamine-N-oxide (TMAO) can activate platelets and increase thrombosis risk in clinical and experimental models. Meanwhile, the patients with coronary artery disease have higher serum TMAO level.
Ruisong Ma +5 more
doaj +4 more sources
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention [PDF]
Frontiers in Cardiovascular Medicine, 2023 Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel therapy, some patients still experience major adverse cardiovascular events (MACEs).
Astuti Giantini +13 more
doaj +2 more sources
Clopidogrel Resistance: An Emerging Problem
University Heart Journal, 1970 DOI: 10.3329/uhj.v5i2.4552University Heart Journal Vol.5(2) July 2009 pp.50 ...
Md Abu Siddique
openalex +4 more sources
Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis [PDF]
Frontiers in Genetics, 2020 In recent years, the relationship between Cyp2C19*2 gene polymorphism and clopidogrel resistance reflected by platelet function assay has been studied extensively, but there is no clear conclusion yet.
Ying Sun +4 more
doaj +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +5 more sources
American Journal of Therapeutics, 2010 Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Kazuo Umemura
openalex +4 more sources
Clopidogrel resistance and genetic factors
Türk Kardiyoloji Derneği Arşivi, 2013 Dual antiplatelet therapy combining aspirin and clopidogrel is the standart care for patients WHO ave ACS or undergoing PCI according to guidelines.Itss well established that the antiplatelet response to clopidogrel varies widely among patients.Patients ...
Alev Arat Özkan
doaj +4 more sources
Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance [PDF]
BMC Medical GenomicsBackground Mediators, genomic and epigenomic characteristics involving in metabolism of arachidonic acid by cyclooxygenase (COX) and lipoxygenase (ALOX) and hepatic activation of clopidogrel have been individually suggested as factors associated with ...
Jei Kim +14 more
doaj +2 more sources